Neuralink rival Precision scores $100M Series C; CEO claims fully implanted 'NAS' device will end paralysis within 3 years
SAN FRANCISCO – Precision Neurotech, a stealthy brain-computer interface competitor to Neuralink, today announced a $100 million Series C led by SoftBank Vision Fund. The company’s CEO, Dr. Elena Voss, declared their proprietary Neural Array System (NAS) is "functionally complete" after human trials showed 98% accuracy in converting neural signals to digital commands. Unlike Musk’s bulky implant, Precision’s NAS is a flexible, sub-dural mesh inserted via a single injection surgery. "We are now in the pre-commercialization phase. Our NAS reduces surgical time from 3 hours to 40 minutes, eliminating the cranial drilling that has made BCIs a niche clinical novelty," Voss said in an exclusive statement. The cash injection will fuel a pivotal Phase III study targeting 500 patients with spinal cord injury. Clinical data suggests subjects regained fine motor control of prosthetic limbs within 6 months. The NAS is expected to gain FDA breakthrough device designation by Q2 2025, positioning Precision to capture the $1.2B BCI market before Neuralink’s timeline slips. Voss’s blunt assessment of rivals: "They’re building racecars. We’re building the highway."